Diabetes Metab J > Volume 31(4); 2007 > Article
Korean Diabetes Journal 2007;31(4):297-301.
DOI: https://doi.org/10.4093/jkda.2007.31.4.297    Published online July 1, 2007.
Peroxisome Proliferator Activated Receptor-delta (PPAR-delta).
Kyung Mook Choi
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine.
The development of novel treatments for the metabolic syndrome is imminent for decreasing the prevalence of type 2 diabetes and cardiovascular disease. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor super-family of ligand-induced transcription factors. Among them, PPAR-alpha and PPAR-gamma are therapeutic targets for dyslipidemia and insulin resistance. Recent studies have uncovered a dual benefit of PPAR-delta for both dyslipidemia and insulin resistance. Furthermore, PPAR-delta enhances fatty acid oxidation and energy uncoupling in adipose tissue and muscle. PPAR-delta activation seems to operate similarly to the caloric restriction and prolonged exercise. Combined effects of PPAR-delta make it a promising therapeutic target for the metabolic syndrome, and ongoing studies about PPAR-delta will improve our knowledge of the physiologic regulation of whole body energy metabolism.

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2022 by Korean Diabetes Association.

Developed in M2PI

Close layer